Nykode Therapeutics AS (OSL:NYKD) Cash And Cash Equivalents : kr1,323.78 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS Cash And Cash Equivalents?

Nykode Therapeutics AS's quarterly cash and cash equivalents declined from Mar. 2024 (kr1,563.12 Mil) to Jun. 2024 (kr1,449.36 Mil) but then stayed the same from Jun. 2024 (kr1,449.36 Mil) to Sep. 2024 (kr1,323.78 Mil).

Nykode Therapeutics AS's annual cash and cash equivalents increased from Dec. 2021 (kr1,937.75 Mil) to Dec. 2022 (kr2,033.76 Mil) but then declined from Dec. 2022 (kr2,033.76 Mil) to Dec. 2023 (kr1,708.52 Mil).

Nykode Therapeutics AS Cash And Cash Equivalents Historical Data

The historical data trend for Nykode Therapeutics AS's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS Cash And Cash Equivalents Chart

Nykode Therapeutics AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

89.44

1,596.67

1,937.75

2,033.76

1,708.52

Nykode Therapeutics AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															1,706.64	1,708.52	1,563.12	1,449.36	1,323.78

Nykode Therapeutics AS Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Nykode Therapeutics AS (OSL:NYKD) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Nykode Therapeutics AS Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Nykode Therapeutics AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (OSL:NYKD) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

VACBF:USA 5VB:Germany

Address

Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349

Website

https://www.nykode.com

Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.

Nykode Therapeutics AS Headlines

No Headlines